Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease Investigational Therapy, NNI-362
28 juin 2023 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., June 28, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., today announced its abstract titled, Clinical Stage Alzheimer’s therapy, NNI-362 Promotes TH+ Neurons Associated with a Reversal...
Nature Publishes Work Demonstrating Clinical ink Technology Sensitivity to Parkinson’s Disease
15 mai 2023 13h30 HE
|
Clinical Ink
Winston Salem, NC, May 15, 2023 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, announces the publication of “Using a smartwatch and smartphone to assess early...
ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinson’s Disease
25 avr. 2023 09h07 HE
|
ZyVersa Therapeutics
Parkinson’s disease (“PD”), the second leading cause of neurodegeneration in the world, is characterized by progressive degeneration of nigrostriatal dopaminergic neurons and intracellular...
Pharma Two B to Present Additional Positive Results from P2B001 Phase 3 Trial at 2023 American Academy of Neurology Annual Meeting
23 avr. 2023 08h30 HE
|
PHARMA TWO B LTD
Results showed P2B001, a once-daily fixed-dose combination of low dose pramipexole and low dose rasagiline, showed comparable efficacy to marketed optimally titrated pramipexole, with significantly...
Neuronascent Announces the Expansion of its Board of Directors
12 avr. 2023 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a clinical-stage, neuron generating, biopharmaceutical company, is pleased to announce the addition of industry leader Emer...
Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancer
06 févr. 2023 08h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications,...
Alterity’s ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
30 janv. 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
10 janv. 2023 10h15 HE
|
Silo Pharma, Inc.
Parkinson's disease, bipolar disorder, and chronic pain targeted in study Study aims to support psilocybin as a potential therapeutic for inflammatory disorders ENGLEWOOD CLIFFS,...
Zhittya Genesis Medicine announces: Free Zoom Webinar: Zhittya Parkinson’s Disease Research Study: 6-Month Patient Follow-Up Report
19 déc. 2022 12h00 HE
|
Zhittya Genesis Medicine Inc
LAS VEGAS, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya”), announced that they will be hosting a webinar on Tuesday, December 20, 2022, at 4:00 PM...
Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs
14 déc. 2022 10h47 HE
|
Clinical Ink
Horsham, PA, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Horsham, Pa.; December 14, 2022 — Clinical ink, a global life science technology company, has partnered with a leading biopharmaceutical organization...